The graduate course «Register-based research: Pharmacoepidemiology - drug use and safety» will provide junior researchers with knowledge on how to conduct register-based research across the Nordic countries.
In CP-North a highly qualified multidisciplinary team of researchers from all major Nordic countries will address a number of societal challenges associated with living with, or being a parent of a child, with a life-long disability in Norden by merging data from national registers with unique health data from quality registers.
Social conditions, such as income, employment and family resources, matter for health, and health matters for participation in society, employment and economic well-being. These associations are well known.
Globally, the leading cause of years of life lost is ischemic heart disease (IHD). In the EU 13.2 mio. patients are diagnosed with IHD(1) of these 700,000 live in the Nordic countries. IHD causes chest pain, myocardial infarcts, reduced physical capacity and reduces life-expectance. IHD is considered a chronic disease and may progress despite current optimal treatment.
Cancer in children is rare. But cancer remains the disease causing the most deaths in children over the age of 1 year. Most children, who die from cancer, do so because the standard treatment doesn't make their disease disappear (resistant disease) or because the disease returns (relapse of the disease). These children are at a high risk of dying from their cancer and we need to develop new treatments for them.
Children in the Nordic Countries are offered many vaccines that protect against a wide variety of specific infectious diseases. Studies from low-income countries indicate that vaccines might also alter the resistance towards other diseases.
The PERAID project proposes to implement personalized medicine (PM) in severe infectious diseases, specifically focusing on the life-threatening necrotizing soft tissue infections (NSTI) as well as the large heterogeneous group of sepsis patients.
Sleep apnea is a prevalent nocturnal breathing disorder and causes a high burden to the affected individuals, as well as to society and economy. However, current diagnostic methods for sleep apnea are complicated and labour-intensive processes involving various shortcomings related to measuring, analysing and reporting of data.
The NORD-STAR clinical trial will provide extremely valuable information on the treatment of early rheumatoid arthritis. The study aims to find out, which is the most effective treatment strategy in early rheumatoid arthritis. As the first trial ever it will compare four different treatment modalities head-to-head.
